La vendita allo scoperto per Skye Bioscience dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Skye Bioscience. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Skye Bioscience (NASDAQ:SKYE) Azioni, Report sulle vendite allo scoperto

Skye Bioscience

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience Inc

Skye Bioscience Inc Ordinary Shares

Skye Petroleum Inc

Biotech

Earnings

News

Guidance

Health Care

General

BEAM

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.47 by 0.68 percent. This is a 14.73 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.619 billion which beat the analyst consensus estimate of $4.566 billion by 1.16 percent. This is a 12.93 percent increase over sales of $4.090 billion the same period last year.

Earnings Beats

Emerson Electric Q4 2024 Adj. EPS $1.48 Beats $1.47 Estimate, Sales $4.619B Beat $4.566B Estimate

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) reported quarterly earnings of $1.41 per share which missed the analyst consensus estimate of $2.21 by 36.2 percent. The company reported quarterly sales of $3.117 billion which missed the analyst consensus estimate of $3.305 billion by 5.69 percent. This is a 0.06 percent increase over sales of $3.115 billion the same period last year.

Earnings Misses

Westlake Q3 2024 Adj. EPS $1.41 Misses $2.21 Estimate, Sales $3.117B Miss $3.305B Estimate

Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.97 by 50.76 percent. This is a 52.91 percent decrease over earnings of $2.06 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.06 billion by 3.82 percent. This is a 1.50 percent increase over sales of $1.00 billion the same period last year.

Hyster Yale Q3 2024 GAAP EPS $0.97 Misses $1.97 Estimate, Sales $1.02B Miss $1.06B Estimate

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 45.08 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $14.27 million which missed the analyst consensus estimate of $14.50 million by 1.58 percent. This is a 17.01 percent decrease over sales of $17.19 million the same period last year.

Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate

Thomson Reuters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.77 by 3.9 percent. This is a 2.44 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $1.720 billion which beat the analyst consensus estimate of $1.713 billion by 0.39 percent. This is a 7.90 percent increase over sales of $1.594 billion the same period last year.

Thomson Reuters Q3 2024 Adj. EPS $0.80 Beats $0.77 Estimate, Sales $1.720B Beat $1.713B Estimate

WIIM

Restaurant Brands International shares are trading lower following worse-than-expected Q3 financial results.

PINC

Premier Q1 2025 Adj. EPS $0.34 Beats $0.25 Estimate, Sales $248.142M Beat $232.843M Estimate

Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) reported quarterly earnings of $0.93 per share which missed the analyst consensus estimate of $0.95 by 2.11 percent. The company reported quarterly sales of $2.291 billion which missed the analyst consensus estimate of $2.307 billion by 0.69 percent. This is a 24.71 percent increase over sales of $1.837 billion the same period last year.

Restaurant Brands Intl Q3 2024 Adj. EPS $0.93 Misses $0.95 Estimate, Sales $2.291B Miss $2.307B Estimate

Edward Jones analyst David Heger downgrades BCE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) from Buy to Hold.

Downgrades

Analyst Ratings

Edward Jones Downgrades BCE to Hold

B of A Securities analyst Dariusz Lozny upgrades MDU Resources Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDU#NYSE">MDU</a>) from Neutral to Buy and lowers the price target from $31 to $17.

Upgrades

Price Target

B of A Securities Upgrades MDU Resources Gr to Buy, Lowers Price Target to $17

TD Cowen analyst Yaron Werber initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Buy rating.

Initiation

TD Cowen Initiates Coverage On Upstream Bio with Buy Rating

Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Prime Video is unveiling an X-Ray Recaps feature to help users stay updated on their favorite shows, even after <a target="_blank" href="https://www.aboutamazon.com/news/entertainment/amazon-prime-video-x-ray-recaps" rel="noreferrer noopener">long breaks between episodes</a>.
Instead of rewinding or searching for plot summaries, viewers can now access spoiler-free, AI-generated recaps to refresh their memory quickly.
X-Ray Recaps uses generative AI to create concise summaries tailored to a user&#8217;s specific point in an episode or season.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722824/apples-services-and-silicon-strategy-to-fuel-margins-justify-high-valuation-analyst" rel="noreferrer noopener">Apple&#8217;s Services And Silicon Strategy To Fuel Margins, Justify High Valuation: Analyst</a>
Whether viewers need a refresher on critical events halfway through a season or have missed crucial plot points, X-Ray Recaps provides clear, relevant context in short text segments.
This feature extends Prime Video&#8217;s existing X-Ray tool, which already offers cast, soundtrack, and trivia information to enhance the viewing experience.
Amazon&#8217;s new feature leverages Amazon Bedrock, an AWS service for creating and scaling AI applications.
The feature combines Bedrock&#8217;s AI and customized models trained on Amazon SageMaker to analyze video segments and subtitles to generate comprehensive yet spoiler-free summaries.
Guardrails ensure that the recaps avoid spoilers and keep the content concise, making it ideal for audiences eager to return to their shows without missing key developments.
Prime Video users can access X-Ray Recaps directly from the detail page or during playback within the X-Ray experience. Once activated, options include summaries for the current episode, the season, or the previous season.
The feature is currently in beta and is available to U.S. customers on Fire TV, with broader device support expected by the end of the year.
At launch, X-Ray Recaps will cover the Amazon MGM Studios Original series.
The move marks Amazon&#8217;s efforts to stay relevant versus streaming giants like Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). Amazon Prime Video started offering lower ad prices than Netflix and other streaming rivals as it competes <a target="_blank" href="https://www.benzinga.com/news/24/07/40042764/amazon-challenges-netflix-with-cheaper-ad-slots-boosts-prime-video-ads-report" rel="noreferrer noopener">for advertiser interest</a>.
Bernstein analyst Mark Shmulik noted Amazon as a substantial investment, even with upcoming <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41737293/amazon-stock-buy-now-pay-off-later-says-analyst" rel="noreferrer noopener">infrastructure spending increases</a>. Shmulik sees Amazon&#8217;s core operations, AWS revenue, and Prime Video investments as key drivers, especially before the holiday season.
He emphasized that Amazon&#8217;s spending tends to yield solid returns, setting up for strong free cash flow in 2025.
<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41692259/amazon-analysts-see-growth-ahead-with-aws-in-early-innings-of-a-big-ai-cycle-advert" rel="noreferrer noopener">Analysts view Amazon Prime Video</a> as a strategic growth driver within Amazon&#8217;s expanding advertising segment. The recent introduction of Prime Video&#8217;s ad-supported tier will likely boost Amazon&#8217;s advertising revenue, with analysts like Truist&#8217;s Youssef Squali projecting significant contributions by fiscal 2025. BMO Capital&#8217;s Brian Pitz also noted that sports content and new AI-driven bidding tools could further enhance ad revenue potential.
Price Action: AMZN stock traded higher by 0.13% to $196.03 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41720954/disney-creates-new-tech-hub-for-ai-and-ar" target="_blank" rel="noreferrer noopener">Disney Creates New Tech Hub For AI and AR</a></li>
</ul>
Photo via Shutterstock

Tech

AMZN

NFLX

Amazon Takes on Netflix With New AI Recaps

TD Cowen analyst Joshua Jennings initiates coverage on CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) with a Buy rating and announces Price Target of $31.

CBLL

TD Cowen Initiates Coverage On CeriBell with Buy Rating, Announces Price Target of $31

B of A Securities analyst Ross Fowler upgrades Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) from Neutral to Buy and raises the price target from $113 to $117.

B of A Securities Upgrades Idacorp to Buy, Raises Price Target to $117

Contracts

RDWR

Radware Expands Customer Relationship With A Prominent US Based Communications Platform As A Service Provider In Multimillion-Dollar Deal

Emeren Enters Co-Development Agreement With Arpinge To Jointly Develop A 300 MW Battery Energy Storage System Portfolio In Southern Italy

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) remains vulnerable to Taiwan&#8217;s surging electricity prices, a shift that could impact the semiconductor industry.
Once a competitive edge, Taiwan&#8217;s low-cost energy has become more challenging to maintain, leading to increased costs for major industrial consumers, the Financial Times <a target="_blank" href="https://www.ft.com/content/cfd77e84-5d5b-47ae-96bd-9973b1c18662" rel="noreferrer noopener">reports</a>.
Taiwan Semiconductor now anticipates that electricity expenses in Taiwan will surpass those in its other significant locations, including the U.S., Japan, and Germany.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41633790/apple-refreshes-macbook-pro-lineup-with-m4-pro-and-m4-max-3nm-chips" rel="noreferrer noopener">Apple Refreshes MacBook Pro Lineup With M4 Pro and M4 Max 3Nm Chips</a>
<a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41706702/nvidia-supplier-tsmc-to-double-advanced-chip-packaging-capacity-as-ai-demand-from-microsoft-amaz" rel="noreferrer noopener">Recent reports indicated</a> the chipmaker will double its advanced packaging capacity by 2025, largely to meet the rising demand for AI chips from major tech firms like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). The company&#8217;s CoWoS packaging technology is in high demand, with Nvidia expected to use more than half of the expanded capacity.
CFO Wendell Huang recently disclosed to investors that power costs in Taiwan have effectively doubled over the past few years and will likely be Taiwan Semiconductor&#8217;s highest globally by 2024.
Taiwan&#8217;s government has raised electricity prices four times since 2022, with increases primarily affecting industrial users like Taiwan Semiconductor.
In line with its broader energy transition, Taiwan aims to boost renewable energy to supply up to 30% of its power by 2030. However, a recent emphasis on scaling back coal and nuclear power has made it increasingly challenging to meet industrial demands.
According to FT, Taiwan relies on coal and liquefied natural gas for over 80% of its energy supply, with renewable sources accounting for only 9.5%.
The rising electricity rates alone may not significantly hinder Taiwan Semiconductor&#8217;s operations, as power costs constitute a minor portion of its overall expenses. However, consistent supply disruptions could threaten Taiwan Semiconductor&#8217;s ability to expand its production capacity in Taiwan, FT writes.
Taiwan Semiconductor stock has gained 89% year-to-date. Investors can gain exposure to the stock through the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) and the First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>).
Price Actions:&nbsp;TSM stock traded higher by 1.17% to $193.80 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41726213/applied-materials-and-lam-research-shift-supply-chains-away-from-china-to-meet-new-us-guidelines" target="_blank" rel="noreferrer noopener">Applied Materials and Lam Research Shift Supply Chains Away from China to Meet New US Guidelines</a></li>
</ul>
Photo by wakamatsu.h via Shutterstock

Government

Regulations

Media

MSFT

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TDIV

Taiwan Semiconductor Faces Rising Energy Costs, Potential Outages Threaten Production

As the United States approaches the election, Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) has seen a notable 5.15% increase in pre-market trading on Tuesday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This surge comes as traders perceive the company&#8217;s stock as a potential indicator of Donald Trump&#8217;s reelection chances.
What Happened: The recent uptick in Trump Media &amp; Technology Group&#8217;s stock is linked to the upcoming U.S. elections. On Monday, DJT closed 12.37% higher at $34.34.
Traders are treating Trump&#8217;s stock as a gauge for his reelection prospects. If Trump wins, his platform, Truth Social, is expected to play a significant role in his communication strategy, akin to his use of X during his presidency, according to <a href="https://www.cnbctv18.com/world/share-of-donald-trumps-social-media-firm-surge-on-eve-of-the-us-election-day-19503834.htm">CNBC</a>. However, if Vice President Kamala Harris wins, the future of Truth Social could face challenges.
See Also: <a href="https://www.benzinga.com/news/24/11/41710411/market-analyst-who-predicted-trumps-2016-win-and-bidens-2020-victory-now-sees-former-president-retak?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Market Analyst Who Predicted Trump&#8217;s 2016 Win And Biden&#8217;s 2020 Victory, Now Sees Former President Retaking The White House With &#8216;Large Majority Of Swing States&#8217;</a>
This development is occurring as the nation gears up for a pivotal election, with market participants closely watching political dynamics. The performance of Trump Media &amp; Technology Group&#8217;s stock reflects broader sentiments regarding the election&#8217;s potential outcomes and their implications for Trump&#8217;s media ventures.
Why It Matters: The election race between Trump and Harris has tightened, with recent polls showing <a href="https://www.benzinga.com/general/politics/24/11/41733277/harris-vs-trump-vice-president-has-two-point-lead-in-final-election-poll-swing-states-remain-clo">Harris maintaining a slight lead</a> over Trump. However, her lead has been shrinking, indicating a closely contested election. This uncertainty adds to the volatility surrounding Trump Media &amp; Technology Group&#8217;s stock.
Additionally, options activity for <a href="https://www.benzinga.com/insights/options/24/11/41717863/this-is-what-whales-are-betting-on-trump-media-technology">Trump Media &amp; Technology</a> has seen significant movement, with deep-pocketed investors showing a divided sentiment. While 36% of these investors are bullish, 48% are bearish, indicating mixed expectations about the company&#8217;s future. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/11/41722178/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

Trump Media (DJT) Stock Rises Over 6% In Pre-Market Ahead Of Presidential Election Eve

Vishay Precision Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPG#NYSE">VPG</a>) sees Q4 sales of $70.000 million-78.000 million vs $79.10 million estimate.

Vishay Precision Group Sees Q4 Sales $70.000M-78.000M vs $79.10M Est

JMP Securities analyst Jonathan Wolleben initiated coverage with a Buy rating on Skye Bioscience (SKYE – Research Report) today and set a price tar...

JMP Securities Initiates a Buy Rating on Skye Bioscience (SKYE)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/10/2024, According to Top Analysts

Skye Bioscience (SKYE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on September 20. Analyst Jonathan W...

Buy Rating Affirmed for Skye Bioscience as Nimacimab Shows Competitive Edge in Obesity Drug Market

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Skye Bioscience (SKYE – Research Report), with a price target of ...

Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on Skye Bioscience (SKYE – Research Report), with a price target ...

Craig-Hallum Sticks to Its Buy Rating for Skye Bioscience (SKYE)

Skye stock rallies 22% following weight-loss drug update

Skye Bioscience ( ($SKYE) ) just unveiled an announcement. Skye Bioscience, Inc. held a special meeting where stockholders approved an amendment to...

Skye Bioscience Approves Incentive Plan Amendments and Leadership Changes

Skye Bioscience ( ($SKYE) ) just unveiled an announcement. Skye Bioscience has announced the appointment of Paul Grayson as the new Chairman of the...

Skye Bioscience Appoints New Chairman for Strategic Growth

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, an acquisi...

Rising High: Compass Pathways reports Q3 earnings

Skye Bioscience (SKYE) announced preliminary data from a diet-induced obesity model in mice. Skye's CB1-inhibiting antibody, nimacimab, achieved si...

Skye Bioscience announces preliminary data from diet-induced obesity model

CANN

CMPS

CRON

CVSI

FFNTF

GPCR

GTBIF

RBRK

RLAY

SHFS

SKYE

TCNNF

TLRY

VKTX

VREOF

Legal

Press Releases

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Management

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Comments

Skye Bioscience

Vendite allo scoperto

Skye Bioscience (NASDAQ:SKYE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO